Encouraging performance in the first nine months

Encouraging performance in the first nine months
Press Release | Jul 01. 2015 06:09 GMT

Chr. Hansen realizes strong organic growth of 9% in the first nine months of 2014/15, narrows organic revenue expectations to 8-9% and declares interim dividend to shareholders.

Chr. Hansen saw solid organic revenue growth of 9% in the first nine months of 2014/15: Cultures & Enzymes Division 8%, Health & Nutrition Division 17% and Natural Colors Division 7%. EBIT before special items increased by 12% to EUR 160 million. Revenue measured in EUR increased by 13%, as Chr. Hansen was positively impacted by the appreciation of the USD.

EUR million Q3 2014/15 Q3 2013/14 Growth YTD 2014/15 YTD 2013/14 Growth
Revenue 228.1 198.1 15% 625.0 550.9 13%
EBIT* 63.8 55.0 16% 159.8 143.2 12%
Profit for the period 45.7 37.4 22% 111.0 93.7 18%
Free cash flow** 53.8 41.2 31% 65.0 46.5 40%
Organic growth 7% 10% 9% 7% 9%
Gross margin 52.4% 50.5% 51.4% 51.7%
EBIT margin* 28.0% 27.8% 25.6% 26.0%
ROIC excl. goodwill 39.0% 35.8% 33.8% 32.1%

* Before special items.

**Before acquisitions, divestments and special items

“The performance in the first nine months of 2014/15 was encouraging with good progress across our divisions and strategic initiatives. Based on this we have narrowed our organic revenue expectations for 2014/15 to 8-9% (previously 7-9%). The EBIT margin is still expected to be above 26.5%, while free cash flow is now expected to be around EUR 150 million (previously above EUR 130 million)” says CEO Cees de Jong.

“Given the strong operational performance and free cash flow generation, we have decided to declare an interim dividend totaling EUR 115 million (DKK 6.57 per share) with a pay-out date of 9 July 2015.”


OUTLOOK FOR 2014/15

The outlook for 2014/15 has been adjusted compared to the announcements of 9 April 2015 and 22 October 2014.

1 July 2015 

Organic revenue growth:   8-9% 
Research & development expenditures incurred (% of revenue):   around 7% 
EBIT margin before special items:   above 26.5% 
Free cash flow before acquisitions, divestments and special items:  around EUR 150 million 

9 April 2015

Organic revenue growth: 7-9%
Research & development expenditures incurred (% of revenue): 7-8%
EBIT margin before special items: above 26.5% 
Free cash flow before acquisitions, divestments and special items: above EUR 130 million

Please see the YTD 2014/15 report for further details.


科汉森是为食品、营养、制药和农业行业开发天然解决方案的一家全球领先的生物科学公司。我们为各种食品、糖果、饮料、膳食补充剂、动物饲料和植物保护开发和生产发酵剂、酶、益生菌和天然色素。我们的产品创新基于大约 40,000 株微生物菌株——我们喜欢称之为“有益菌群”。我们的解决方案帮助食品制造商实现以更少的资源生产更多的产品,同时也减少了化学添加剂和其他合成物添加剂的使用,这使得我们的产品与当今世界息息相关。可持续性是科汉森改善食物和健康的愿景不可分割的一部分。2019 年,科汉森被 Corporate Knights 评为全球最可持续发展的公司,这要归功于我们为可持续发展付出的巨大努力以及我们与客户建立的众多合作伙伴关系。145 年来,我们一直在不断地为我们的合作伙伴以及全球终端消费者创造价值。令我们感到自豪的是,每天有超过 10 亿人在消费含有我们天然成分的产品。科汉森成立于 1874 年,并已在哥本哈根证券交易所上市。

NewsAttachments

共享